Data showed that fracture risk rises briefly after menopausal hormone therapy discontinuation, then falls below never-users.

In a recent interview, Andrea Pezzella, MD, URPS, FACOG, of Southern Urogynecology Wellness & Aesthetics in West Columbia, South Carolina, shared insights on the newly FDA-approved Neuspera integrated ...

An expert summarizes that Tara-002, a novel immunotherapy derived from Streptococcus pyogenes, is showing promising results in a phase 2 trial for non–muscle-invasive bladder cancer—particularly in ...

Metastasis-directed radiotherapy without systemic therapy (MRWS) demonstrated promising efficacy with manageable safety in patients with oligometastatic clear cell renal cell carcinoma (ccRCC), ...

According to Song, novel aspiration technologies are reshaping not only care delivery, but also long-term treatment outcomes. The emergence of new aspiration devices for stone disease has been a ...

The WATER IV PCa trial is comparing first-line Aquablation therapy with radical prostatectomy for the treatment of patients with localized prostate cancer.

Panelists discuss how the treatment paradigm for androgen deprivation therapy is evolving from traditional injectable GnRH agonists to include oral GnRH antagonists like relugolix, which offer more ...

In this video, Bridget Lang Findlay, MD, a reconstructive urologist with Mayo Clinic in Phoenix, Arizona, focuses on her study examining long-term bladder management strategies among women with spinal ...

One consideration is the setting in which the procedure is performed. The FDA recently expanded the label for the Rezūm System, which now includes prostate volumes up to 150 cm 3, In this interview, ...

The American Medical Association (AMA) has announced a new category III CPT code for the use of Avvio Medical’s Enhanced Lithotripsy System (ELS) for acoustic enhancer microbubble cavitation (AEMC) ...

Treatment with mitomycin for intravesical solution (Zusduri, formerly UGN-102) was associated with durable, long-term complete responses (CRs) in patients with low-grade, intermediate-risk non–muscle ...

Panelists discuss the critical unmet need for more personalized treatment in non–muscle-invasive bladder cancer (NMIBC), emphasizing the role of biomarkers, emerging modalities like radiation, and ...